MedTrace Logo

Safety and Comfort of AL-4943A Ophthalmic Solution

NCT01326858 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-03-03

No results posted yet for this study

Summary

The purpose of this study is to assess the ocular comfort and safety of olopatadine hydrochloride opthalmic solution. 0.7%.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

Olopatadine hydrochloride ophthalmic solution, 0.7%

Treatment A

DRUG

Olopatadine hydrochloride ophthalmic solution vehicle

Treatment B, inactive ingredients used as placebo

DRUG

Ketotifen fumarate ophthalmic solution, 0.025%

Treatment C

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Abhijit Narvekar, MS, MBBS · Alcon Research

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-06-30
Completion
2011-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01326858 on ClinicalTrials.gov